Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 145.21M P/E - EPS this Y 4.50% Ern Qtrly Grth -
Income -39.33M Forward P/E 2.23 EPS next Y 157.10% 50D Avg Chg -23.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -23.00%
Dividend N/A Price/Book 1.47 EPS next 5Y - 52W High Chg -47.00%
Recommedations 2.00 Quick Ratio 3.65 Shares Outstanding 159.10M 52W Low Chg 19.00%
Insider Own 7.74% ROA -23.21% Shares Float 146.77M Beta 1.44
Inst Own 17.03% ROE -40.97% Shares Shorted/Prior 12.18M/11.58M Price 0.91
Gross Margin - Profit Margin - Avg. Volume 2,028,708 Target Price -
Oper. Margin - Earnings Date May 10 Volume 1,696,404 Change -4.26%
About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Citius Pharmaceuticals, Inc. News
03/18/24 Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
03/12/24 Sidoti Events, LLC's Virtual March Small-Cap Conference
03/07/24 Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
02/26/24 Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration
02/23/24 Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
02/14/24 Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
02/14/24 Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
02/11/24 Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)
01/23/24 Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors
01/02/24 Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters
01/02/24 Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
12/03/23 We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully
11/14/23 Sidoti Events, LLC’s Virtual November Micro-Cap Conference
11/09/23 Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023
10/31/23 Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor
10/24/23 Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
09/21/23 Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
09/18/23 Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023
09/13/23 Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir
09/08/23 Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™
CTXR Chatroom

User Image Cashflow62 Posted - 10 hours ago

$CTXR decent close.

User Image AndySz Posted - 10 hours ago

$CTXR I wouldnt be satisfied with anything under $5. Maybe not on Monday Maybe not by May But maybe by July

User Image fcollage Posted - 13 hours ago

$CTXR Copilot The FDA’s acceptance of the Biologics License Application (BLA) resubmission for LYMPHIR™ by Citius Pharmaceuticals, Inc. (CTXR) holds considerable importance for several reasons: Path to Approval: The acceptance indicates that the FDA has found the application complete and suitable for further evaluation. Clinical Impact: LYMPHIR™ is intended for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. If approved, it could provide a new therapeutic option for patients facing this challenging condition. Market Potential: Approval of LYMPHIR™ would open up a new revenue stream for Citius Pharmaceuticals. Investor Confidence: Regulatory milestones like BLA acceptance often boost investor confidence. Competitive Landscape: If approved, LYMPHIR™ would compete with treatments in the market. The FDA’s acceptance of the BLA resubmission represents a critical step toward potential drug approval, clinical impact, and business growth.

User Image adaminthemiddle Posted - 13 hours ago

@Keepitmoving no problem–considering the sarcasm I’m reading in your reply, I would reread what you just wrote to me and see if literally anything you’ve written on the $CTXR chat board applies to that. Everybody has lost money on this board, you don’t have to project your negativity in every post.

User Image GaryBezos Posted - 14 hours ago

$CTXR next week we shall see if we can glaze the $1 mark . We coming . Have a great weekend everyone

User Image gottsbrain Posted - 15 hours ago

$CTXR could someone tell me the benefit for ctxr shareholders with the upcomming spin off in citius oncology? Some experts around?

User Image donein12 Posted - 15 hours ago

$CTXR CTXR still holding gains this late in the day before a 3 day weekend is a good sign.

User Image Bronco6970 Posted - 15 hours ago

$CTXR level 2 showing a lot of bids above .90!

User Image chknbskt Posted - 15 hours ago

$CTXR wen $1, wen moon?

User Image TotallyTrading Posted - 16 hours ago

$CTXR I predict some last-hour action. Who’s with me?

User Image ShareStructure Posted - 16 hours ago

$CTXR It amazes me how even increments like every .10 cents or every $1.00 can be resistance as though breaking those resistances will make or break someone's bank. Too many traders and not enough longs (investors) has killed the past CTXR momentum on many occasions over the 4 years I've been investing in it.

User Image BeMarsh Posted - 16 hours ago

$CTXR - somebody knows something….

User Image Miker521 Posted - 16 hours ago

$CTXR

User Image Bronco6970 Posted - 17 hours ago

$CTXR this ain’t no pump and dump, this is the real deal. Let’s go!

User Image Clam_Digger Posted - 17 hours ago

$CTXR 🤑🤑🤑🤑🤑

User Image CTXRforLife Posted - 17 hours ago

$CTXR

User Image BEASTSTOCKALERTS Posted - 18 hours ago

$CTXR Lfg !

User Image SuperStonkMagic Posted - 18 hours ago

$CTXR 🔥🔥🔥

User Image michaelre Posted - 18 hours ago

$CTXR

User Image MoneyManVino Posted - 18 hours ago

$CTXR @TwongStocks Do you happen to know if they plan on using the same manufacturer for commercial manufacturing once they are approved, or a CMO?

User Image BleedRedSmokeGreen Posted - 18 hours ago

$CTXR the way this thing goes up on no news

User Image BleedRedSmokeGreen Posted - 18 hours ago

$CTXR dayuuuuuum

User Image TechnicalFun Posted - 18 hours ago

$CTXR been holding for years slowly averaging down. Last week i picked up some AUG call options and glad to see the return but won't be selling a few for a while. Conservative pt is 3.5

User Image GaryBezos Posted - 19 hours ago

$CTXR

User Image Keepitmoving Posted - 19 hours ago

$CTXR Manipulation at its finest. Zero news to report unless you want to highlight the fact that ML has to be the longest f*cking trial ever. I’m happy with the house of cards pump. Keep it going so I can exit

User Image Cooch23 Posted - 19 hours ago

$CTXR 🤣

User Image jobix Posted - 19 hours ago

$CTXR like my average here,holding strong. .....regaining compliance is uncle Lenny's fiduciary responsibility to keep his check coming.see you at 1.20 soon!

User Image PokerMunkee Posted - 19 hours ago

$CTXR Feeling like a f'n genius for buying heavily in the .60s. Easy money. Selling after $2 when ML TLD shows superiority.

User Image Icantgetup Posted - 19 hours ago

$CTXR I would really like to see this SP grow steady like. I have family members in the red because of my recommendations to buy back around $1.50

User Image Icantgetup Posted - 19 hours ago

$CTXR I would have bought at 40 cents. Right here.

Analyst Ratings
HC Wainwright & Co. Buy Feb 14, 24
HC Wainwright & Co. Buy Aug 10, 23
HC Wainwright & Co. Buy Aug 1, 23
HC Wainwright & Co. Buy May 30, 23
HC Wainwright & Co. Buy Apr 3, 23
HC Wainwright & Co. Buy Mar 29, 23
HC Wainwright & Co. Buy Jan 18, 22
Maxim Group Buy Nov 30, 21
HC Wainwright & Co. Buy May 23, 18